Trial
NCT00775502
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Kyowa Kirin Co., Ltd.
Collaborators
Kyowa Hakko Kirin Pharma, Inc.
Condition
Multiple Myeloma
Intervention
BIW-8962
Why stopped
lack of efficacy in Multiple myeloma
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-25